Skip to main content



Local Cdiff information for Idaho

Idaho

Learn about C. diff providers, regulation, clinical trials, and advocacy efforts in Idaho.



Local Cdiff information for Idaho

Idaho

Learn about C. diff providers, regulation, clinical trials, and advocacy efforts in Idaho.

Providers

Digestive Health Clinic

Digestive Health Clinic
Idaho Endoscopy Center

Central Contact
Ph: (208)489-1900
Fax: (208)375-5286

VISIT WEBSITE>

Locations

Nampa Digestive Health Clinic & Nampa Idaho Endoscopy Center
5080 E. Commerce St.
Nampa, ID 83687

Digestive Health Clinic & Idaho Endoscopy Center
6259 W. Emerald St.
Boise, ID 83704

Regulation

C. diff Infections

Total Reported Cases: 199
Hospital Onset: 199
Community Onset: Not reported
Related Deaths: Not reported

Available Reports

Annual Progress based on SIR: 0.66
CDC STATE PROGRESS REPORT >
STATE REPORTING >

State Reporting Laws

Data Submission Required: No
Data Publicly Available: No
Data Validated: Yes
Facility-specific Data Publicly Reported: No
LTC Facility Submission Required: No
LTC Facility Data Publicly Reported: No
Law/Regulation: Not available
STATUTE >

State Contact

Kathryn Turner, PhD, MPH
Program Manager
Idaho Department of Health and Welfare
Office of Epidemiology, Food Protection, and Immunization
450 West State St., 4th Floor
Boise, 83720
(208) 334-5870
(208) 332-7307
EMAIL KATHRYN TURNER, PHD, MPH >

CLINICAL TRIALS

RESTORATiVE303

Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Trial No. NCT06237452
Type: Interventional
Recruitment: Recruiting
Sponsor: Vedanta Biosciences, Inc
Contact: Mary Garfield
EMAIL >
Gender: All
Age: 12 Years and older
Vedanta Biosciences has teamed up with Science37 to provide a site-less, decentralized approach. This means the study can be done remotely and the product comes to you, in your home. This allows applicants who are not near a study site or unable to travel to participate and receive treatment. You can sign up for the decentralized study here.

LMN-201

Official Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study of LMN-201 for Prevention of C. Difficile Infection Recurrence
Trial No. NCT05330182
Type: Interventional
Recruitment: Recruiting
Sponsor: Lumen Bioscience, Inc.
Contact: Carl Mason, MD
EMAIL >
Gender: All
Age: 18 Years and older